GSK, Shenzhen Neptunus Of China To Collaborate On Flu Vaccines
This article was originally published in PharmAsia News
Executive Summary
U.K.-based GlaxoSmithKline and China's Shenzhen Neptunus plan a joint venture to make influenza vaccines in China, with GSK holding a 40 percent stake with options to buy more. The deal is expected to increase the British company's presence in China where it hopes to trade on its adjuvant technology. The five-year plan for the joint venture calls for production of seasonal, pre-pandemic and pandemic flu vaccine for China, Hong Kong and Macau. GSK also intends to expand its vaccine-manufacturing business in other parts of Asia. (Click here for more
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.